2024-02-13T00:00:00.000+11:00
Ongoing

Beigene BGB-11417-203

Beigene BGB-11417-203
Waldenström’s Macroglobulinemia

An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of BCL2 Inhibitor BGB-11417 in Patients With Relapsed/Refractory Waldenström’s Macroglobulinemia

An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of BCL2 Inhibitor BGB-11417 in Patients With Relapsed/Refractory Waldenström’s Macroglobulinemia

Trial overview

Topic

Waldenström’s Macroglobulinemia

Trial registration

Number: NCT05952037

Study details

This study will evaluate the safety and efficacy of the BCL2 inhibitor BGB-11417 in participants with relapsed/refractory Waldenström's Macroglobulinemia (R/R WM) in 3 cohorts.

Further information

Please click here for more information

Location

GenesisCare North Shore – PI: Dr David Kilman

GenesisCare North Shore – PI: Dr David Kilman :::

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.